Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levomilnacipran ER Fixed-Dose Study in Major Depressive Disorder
NCT00969709Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Sep 2009
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levomilnacipran in major depressive disorder (MDD) (4 arms), sponsored by Forest Laboratories. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 8 weeks. Started Sep 2009; status: completed.
02
Drugs
levomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00969709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00969709.